Coca-Cola Amatil Ltd. Jun 11

  • ID: 2042487
  • June 2011
  • Standard & Poors
1 of 3

Strategic importance of Coca Cola Amatil Ltd. to The Coca-Cola Co., which owns 29.5% of the company Relatively stable earnings from the Australian and New Zealand non-alcoholic beverages segments Leading market share across its territories in the carbonated soft-drinks category A strong and diversified brand portfolio and efficient distribution capabilities Exposure to volatile costs for raw materials, such as sugar, aluminum, and PET resin Exposure to relatively higher earnings volatility from its Asian operations and the challenges associated with the Indonesian market Potential challenges associated with diversification into segments outside of its traditional soft-drinks business The ratings on Australian-based soft-drinks and food producer Coca-Cola Amatil Ltd. (CCA) incorporate a level of implied support from the company's 29.5 %-major shareholder, Coca-Cola...

Companies mentioned in this report are: Coca-Cola Amatil Ltd.,Coca-Cola Amatil (Australia) Pty Ltd.
Action: Review

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

Coca-Cola Amatil Ltd.,Coca-Cola Amatil (Australia) Pty Ltd.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.